Therapeutic potential for GIP receptor agonists and antagonists

Research output: Contribution to journalArticlepeer-review

91 Citations (Scopus)


Glucose-dependent insulinotropic polypeptide (GIP or gastric inhibitory polypeptide) is a 42-amino-acid hormone, secreted from the enteroendocrine K cells, which has insulin-releasing and extrapancreatic glucoregulatory actions. However, the unfavourable pharmacokinetic profile and the weak biological effects of native GIP limit its effectiveness for the treatment of type 2 diabetes. To overcome this, longer-acting GIP agonists exhibiting enzymatic stability and enhanced bioactivity have been generated and successfully tested in animal models of diabetes. Thus,GIP receptor agonists offer one of the newest classes of potential antidiabetic drug. GIP is also known to play a role in lipid metabolism and fat deposition. Accordingly, both genetic and chemical ablation of GIP signalling in mice with obesity-diabetes can protect against, or even reverse many of the obesity-associated metabolic disturbances. Strong parallels exist with the beneficial metabolic effects of Roux-en-Y gastric bypass in obese, insulin-resistant humans that surgically ablates GIP-secreting K cells. The purpose of this article is to highlight the therapeutic potential of GIP-based therapeutics in the treatment of type 2 diabetes and obesity. (C) 2009 Elsevier Ltd. All rights reserved.
Original languageEnglish
Pages (from-to)499-512
JournalBest Practice and Research: Clinical Endocrinology and Metabolism
Issue number4
Publication statusPublished (in print/issue) - Aug 2009


Dive into the research topics of 'Therapeutic potential for GIP receptor agonists and antagonists'. Together they form a unique fingerprint.

Cite this